Mesenchymal stem cells (MSC) were described by Friedenstein in the 1970s as being a group of bone marrow non-hematopoietic cells that are the source of fibroblasts. Since then, knowledge about the therapeutic potential of MSCs has significantly increased. MSCs are currently used for the treatment of many diseases, both in adults and children. MSCs are used successfully in the case of autoimmune diseases, including rheumatic diseases, diabetes mellitus type 1, gastroenterological and neurological diseases. Moreover, treatment of such organ disorders as damage or hypoxia through application of MSC therapy has shown to be satisfactory. In addition, there are some types of congenital disorders, including osteogenesis imperfecta and Spinal Muscular Atrophy, that may be treated with cellular therapy. Most studies showed no other adverse effects than fever. Our study is an analysis that particularly focuses on the registered trials and results of MSCs application to under 18 patients with acute, chronic, recurrent, resistance and corticosteroids types of Graft-versus-Host Disease (GvHD). Stem cells currently play an important role in the treatment of many diseases. Long-term studies conducted on animals have shown that cell therapy is both effective and safe. The number of indications for use of these cells in the course of treatment of people is constantly increasing. The results of subsequent studies provide important data justifying the application of MSCs in the course of treatment of many diseases whose treatment is ineffective when utilizing other approaches.
2. Bajek A., Olkowska J., Drewa T.: Mesenchymal stem cells as a therapeutic tool in tissue and organ regeneration. Postepy Hig Med Dosw 24;65:124-32,2011.
3. Ball L.M., et al.: Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br J Haematol. 163(4):501-9. 2013. doi:
4. Barry F.P., et al.: The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105). Biochem Biophys Res Commun 265(1):134-9, 1999.
5. Boruczkowski D., Korytowska-Niklas A., Bręborowicz A.: Zastosowanie komórek macierzystych w terapii chorób układu oddechowego - możliwości i nadzieje. Alergia Astma Immunologia 18 (3): 170-174, 2013.
6. Boruczkowski D., et al.: Krew pępowinowa. Część trzecia - przyszłość [Cord blood. Part three - the future]. Nowa Pediatria 3:61-65, 2011.
12. Dominici M., et al.: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4):315-7,2006.
13. Fang B, et al.: Cotransplantation of haploidentical mesenchymal stem cells to enhance engraftment of hematopoietic stem cells and to reduce the risk of graft failure in two children with severe aplastic anemia. Pediatr Transplant 13(4):499-502,2009. doi:
14. Farivar S., et al.: Neural differentiation of human umbilical cord mesenchymal stem cells by cerebrospinal fluid. Iran J Child Neurol 9(1):87-93, 2015.
15. Friedenstein A.J., et al.: Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 17(4):331-40, 1974.
16. Gentili C., Torre M., Cancedda R.: Tissue engineering approaches in skeletal pediatric disorders. Eur J Pediatr Surg 24(3):263-9, 2014. doi:
20. Hibi H., Yamada Y., Ueda M., Endo Y.: Alveolar cleft osteoplasty using tissue-engineered osteogenic material. Int J Oral Maxillofac Surg 35(6):551-5,2006.
21. Hu J., et al.: Long term effects of the implantation of Wharton’s jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocr J 60(3):347-57, 2013.
22. Introna M., et al.: Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transplant. 20(3):375-81, 2014. doi:
26. Krenska A., et al.: The use of mesenchymal stem cells in therapy of steroid-resistance chronic refractory graft-versus-host disease after hematopoietic stem cell transplantation. Medical and Biological Sciences 28, 3, 57-61, 2014.
27. Kurtzberg J., et al.: Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. Biol Blood Marrow Transplant 20(2):229-35, 2014. doi:
29. Le Blanc K., et al.: Developmental Committee of the European Group for Blood and Marrow Transplantation. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 10;371:1579-86, 2008. doi:
36. Prasad V.K., et al.: Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 17(4):534-41, 2011. doi:
39. Sun Y., Zhang F.S., Zhang Z.Y.: Immunoregulatory effect of bone marrow mesenchymal stem cells on regulatory T cells in patients with systemic lupus erythematosis. Zhonghua Nei Ke Za Zhi 46(12):1018-21, 2007.
40. Tyndall A.: Application of autologous stem cell transplantation in various adult and pediatric rheumatic diseases. Pediatr Res 71(4 Pt 2):433-8, 2012. doi:
43. Wakitani S., et al.: Autologous bone marrow stromal cell transplantation for repair of full-thickness articular cartilage defects in human patellae: two case reports. Cell Transplant 13(5):595-600, 2004.
44. Wernicke C.M., et al.: Mesenchymal stromal cells for treatment of steroid-refractory GvHD: a review of the literature and two pediatric cases. Int Arch Med 15;4(1):27, 2011.doi: